SPI supplies products such as excipients and antacid actives, as well as formulation development and services
SPI Pharma, a supplier to pharmaceutical and nutraceutical formulation marketers, has announced an agreement with Azelis Americas, a service provider in the specialty chemicals and food ingredients industry. Per the agreement, Marcor, an Azelis Americas company, will distribute SPI’s product lines in the United States, while Azelis Canada Pharma Division will be responsible for the Canadian marketplace.
SPI supplies products such as excipients and antacid actives, as well as formulation development and services. This agreement covers the company’s mannitol, fructose, maltose, antacid actives, metal salts, surface modified sodium bicarbonate, ODT drug delivery systems and vaccine adjuvants. The SPI products are set to enable additional formulations, chewable tablets, nutraceutical tablets, the companies say.
Scott Thomson, CEO of SPI Pharma, says: "We are excited to partner with Azelis Americas in the US and Canada. Azelis Americas and SPI Pharma have a like-minded approach to providing innovative solutions to the market, as well as a very complementary product range. The Azelis network of application labs and their formulation expertise will add depth to SPI Pharma's ability to deliver on our goal of solving formulation challenges for our customers. With the Azelis Americas team of sales, service and technical experts behind us, we look forward to the great results they will bring in the US and Canada."
Frank Bergonzi, CEO and President of Azelis Americas, adds: "Our latest partnership with SPI Pharma expands Azelis Americas' ability to serve customers in the pharmaceutical and nutraceutical industries. SPI Pharma is a leader in providing pharmaceutical solutions. With the new excipient product lines available from SPI Pharma in combination with our existing products, our customers will now have access to the broadest range of specialty ingredients in the market. Add the expertise of our leading application labs and 'innovation through formulation' becomes a tangible result for all of Azelis' and SPI Pharma's customers, as well as the broader marketplace."
The agreement follows the recent announcement that Azelis will distribute SPI products in the UK and Ireland.